Scientific Advisory Board
Five practising dermatologists from tier-1 Spanish institutions form the founding Scientific Advisory Board, advising Legit.Health on clinical validity, scientific direction, and key opinion leader access. As we enter our priority markets, the board is being extended with international reference dermatologists.
👨⚕️
Dr. Ricardo Ruiz
Clínica Dermatológica Internacional (CDI Madrid)
"Legit.Health's technology is a necessary breakthrough in the world of dermatology. It is not only the best tele-dermatology tool, but also a very useful complement to the face-to-face consultation."
👨⚕️
Dr. Sergio Vañó
Hospital Univ. Ramón y Cajal (Madrid)
👨⚕️
Dr. Ramón Grimalt
Universitat Internacional de Catalunya (UIC Barcelona)
👨⚕️
Dr. Pedro Rodríguez
Clínica Dermatológica Internacional (CDI Madrid)
👨⚕️
Dr. Fernando Alfageme
Hospital Univ. Puerta de Hierro (Madrid)
"In the specific case of Hidradenitis Suppurativa, Legit.Health's algorithm helps my entire service to diagnose with greater speed and reliability, even if they are not experts in the pathology."
What the SAB does
Algorithm validation
Each new severity scoring algorithm (PASI, SCORAD, IHS4, AUAS, SALT, GPPGA, AGPPGA) is reviewed and validated by SAB members before deployment.
Peer-reviewed co-authorship
SAB members are listed as authors on the 9 peer-reviewed papers validating our algorithms.
KOL access
Access to the broader dermatology community in Spain and Europe.
Regulatory review
Reviews regulatory submissions for clinical evidence and intended use claims.
Expanding the board into strategic markets
As Legit.Health advances in its priority markets, the board is being extended with reference dermatologists (KOLs) in the countries where we are actively growing: Brazil, the UK, and the US. A local reference does two things at once that a commercial hire cannot: it anchors clinical credibility with regulators and payers, and it opens hospitals and insurers far faster through peer trust.
🇧🇷
Brazil
One of the largest dermatology markets in the world, where we already generate revenue. A Brazilian reference supports local adoption and LATAM credibility.
🇬🇧
United Kingdom
NHS entry led by Chris McKee (UK Sales Director). A UK reference underpins trust-level adoption and NHS clinical endorsement.
🇺🇸
United States
A US reference reinforces FDA clinical credibility and, post-clearance, payer and market-access conversations.
The expansion is deliberately capital-light: reference dermatologists join on honoraria, not salary. The bridge funds their honoraria, meetings and travel (see Use of Funds).
Track record
- 9 peer-reviewed publications (JAAD, JEADV, JID Innovations, JMIR Dermatology, European Archives of Oto-Rhino-Laryngology, Skin Research & Technology, Skin Health and Disease)
- 6 years of continuous collaboration since 2020